Clinical Efficacy Evaluation and Mechanism Study of Anti-Hepatic Fibrosis Effectively Treated Prescription by Supplementing Deficiency and Clearing Collaterals

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100049795

Enrollment

Unknown

Registered

2021-08-09

Start date

2021-08-01

Completion date

Unknown

Last updated

2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver fibrosis

Interventions

treatment group:Qijia Fuzheng Rougan Granules

control group:Compound soft-liver tablet of turtle armour

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for chronic hepatitis B fibrosis; 2. Diagnostic criteria of TCM syndrome of Qi deficiency and collateral obstruction; 3. Aged between 18-65 years old; 4. Good compliance and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Those with poor compliance; 2. Those who are participating in other scientific research projects; 3. Diagnosed as severe chronic hepatitis B or prone to severe hepatitis; 4. Alcoholic, drug-related, infectious, hereditary, immune, and other viral liver diseases; 5. Decompensated patients after hepatitis; 6. Patients with severe heart, brain, lung and kidney diseases or tumors; 7. Pregnant women or lactating women; mentally ill or unable to cooperate.

Design outcomes

Primary

Measure	Time frame
Alanine aminotransferase;Aspartate aminotransferase;total bilirubin;platelet;DNA;Hepatitis B Surface Antigen;Hepatitis B Surface Antibody;Hepatitis B E Antigen;Hepatitis B E antibody;Hepatitis B core antibody;	—

Countries

China

Contacts

Public ContactFeng Quansheng

Chengdu University of Traditional Chinese Medicine

fengqs118@163.com+86 13688120528

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026